GBS logo

GBS (GBS) Stock

Profile

Full Name:

GBS Inc.

Sector:

Healthcare

Country:

United States

IPO:

23 December 2020

Indexes:

Not included

Description:

GBS Inc. operates as a biosensor diagnostic technology company. Its principal product is Saliva Glucose Biosensor, a saliva glucose monitoring system for diabetes management. The company also focuses on developing other diagnostic tests in the areas of biochemistry, tumor markers, immunology, hormones, and other biomarkers. It has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. GBS Inc. was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was founded in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Nov 11, 2022

Recent annual earnings:

Aug 11, 2022
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Apr 10, 2017

Analyst ratings

Recent major analysts updates

No data about analysts updates

Screeners with GBS included

No data

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Similar stocks

Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)
Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)
Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)
GBS
globenewswire.com16 December 2024

Real-World Evidence Study Strengthens the Body of Evidence Supporting ANX005 for Treatment of GBS ANX005 Phase 3 Population Was Matched 1:1 on Prespecified Criteria with Patients in International GBS Outcomes Study (IGOS) Matched Cohort Study Showed Early and Greater Benefits of ANX005 over IVIg or PE in Muscle Strength and Functional Outcomes Across Multiple Measurements Conference Call and Webcast Today at 8:30 a.m. ET BRISBANE, Calif.

FAQ

  • What is the primary business of GBS?
  • What is the ticker symbol for GBS?
  • Does GBS pay dividends?
  • What sector is GBS in?
  • What industry is GBS in?
  • What country is GBS based in?
  • When did GBS go public?
  • Is GBS in the S&P 500?
  • Is GBS in the NASDAQ 100?
  • Is GBS in the Dow Jones?
  • When was GBS's last earnings report?
  • When does GBS report earnings?

What is the primary business of GBS?

GBS Inc. operates as a biosensor diagnostic technology company. Its principal product is Saliva Glucose Biosensor, a saliva glucose monitoring system for diabetes management. The company also focuses on developing other diagnostic tests in the areas of biochemistry, tumor markers, immunology, hormones, and other biomarkers. It has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. GBS Inc. was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was founded in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

What is the ticker symbol for GBS?

The ticker symbol for GBS is NASDAQ:GBS

Does GBS pay dividends?

No, GBS does not pay dividends

What sector is GBS in?

GBS is in the Healthcare sector

What industry is GBS in?

GBS is in the Medical Devices industry

What country is GBS based in?

GBS is headquartered in United States

When did GBS go public?

GBS's initial public offering (IPO) was on 23 December 2020

Is GBS in the S&P 500?

No, GBS is not included in the S&P 500 index

Is GBS in the NASDAQ 100?

No, GBS is not included in the NASDAQ 100 index

Is GBS in the Dow Jones?

No, GBS is not included in the Dow Jones index

When was GBS's last earnings report?

GBS's most recent earnings report was on 11 November 2022

When does GBS report earnings?

The date for GBS's next earnings report has not been announced yet